Premium
α‐Glucosidase inhibitor, miglitol decreases the expression of inflammatory cytokines induced by hyperglycemia
Author(s) -
Fukaya Nanae,
Tanaka Yutaro,
Mochizuki Kazuki,
Goda Toshinao
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a1054-a
Subject(s) - postprandial , streptozotocin , inflammation , proinflammatory cytokine , medicine , endocrinology , diabetes mellitus , chemistry
Recent studies suggested that α‐Glucosidase inhibitors might prevent inflammation by inhibiting postprandial hyperglycemia. To explore whether miglitol prevents inflammation induced by hyperglycemia, we asministrated miglitol to streptozotocin‐treated rats in this study. Streptozotocin treatment remarkably induced hyperglycemia after 5 days following the treatment. Microarray analysis of blood cells revealed that the leucocyte‐derived expressions of not only IL1β but also S100a4/6/8/9 genes, which are putative inflammatory cytokines, were induced by streptzotocin treatment. Moreover, the induction of these genes by streptozotocin was significantly inhibited in the rats fed a diet containing miglitol for 20 days compared with those fed a control diet. These results suggest that S100a4/6/8/9 might be useful biomarkers for hyperglycemia at early stage, and that miglitol decreases the risk of hyperglycemia‐induced inflammation by inhibiting the expression of inflammatory cytokines.